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Abstract
Background: The use of flaps in vulvar cancer-related reconstruction has been increasing, but few studies have
evaluated the outcome and quality of life of patients after this surgery. The purpose of this study was to evaluate
the outcomes of vulvar reconstruction using musculocutaneous/skin flaps in patients with advanced and recurrent
vulvar malignancies.
Methods: Patients with vulvar malignancies who underwent vulvar reconstruction using different types of flaps
were retrospectively reviewed. Patient outcomes were evaluated with a focus on quality of life and prognosis.
Results: Thirty-six patients were enrolled, 58.33 % of them used anterolateral thigh flap (ALT), 16.67 % of them used
pudendal thigh flap (PTF), 11.11 % of them used deep omferior epigastric perforator (DIEP) and gracilis myocutaneous
flap were used in 2.78 % of the patients, the other 11.11 % patients used two types of flaps. Eleven patients
(30.56 %) developed complications, including 5 patients (13.89 %) with partial necrosis, 5 (13.89 %) with
minimal wound dehiscence and 1 (2.78 %) with flap cellulitis. All patients who developed partial necrosis
(13.89 %) underwent reoperation. The mean verbal rating scale score was 1.44 before reconstruction and 0.17
after surgery (P < 0.0001). The mean performance status was 1.67 before surgery and improved to 0.31 after
surgery (P < 0.0001). The median overall follow-up time after vulvar reconstruction was 9 months. Twenty-one
patients (58.3 %) developed recurrence at a median interval of 5 months after vulvar reconstruction. After a
median follow-up time of 14 months, 41.7 % of the patients were living and disease-free. The 5-year survival
of the 36 patients was 53.8 %.
Conclusion: Soft tissue reconstruction in patients undergoing resection of advanced/recurrent vulvar malignances is
associated with a low rate of postoperative complications, decreased pain, and improved functional status. Although
the recurrence rate in this patient population is high, a reasonable proportion of patients who undergo resection for
advanced/recurrent vulvar cancer and reconstructive surgery appear to benefit.
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Background
Surgery is the mainstay treatment for vulvar malignan-
cies. However, vulvar malignancies often have a high risk
of relapse that may reach 65 % at the scheduled follow-
up [1]. Local recurrence is more common than distant
metastasis in patients with larger tumors [2], and can be
successfully treated by tumor excision or irradiation.
However, multiple surgeries and radical excision often
leaves a large defect without sufficient tissue for cover-
age, which delays wound healing and increases post-
operative morbidity. All of these factors have an adverse
impact on the patient’s quality of life (QoL), which is
generally accepted as an important outcome parameter,
in addition to the long-term survival, mortality and
complication-related morbidity [3]. Therefore, vulvar
reconstruction should be considered after radical surgi-
cal treatment to reduce the morbidity and improve the
patient’s QoL.
In recent years, the use of myocutaneous/muscle flaps
for reconstruction has increased in the treatment of gy-
necologic malignancies [4–6]. However,few studies have
evaluated the outcomes and QoL of patients who have
undergone this surgical treatment. In the present study,
we evaluated the outcomes of different types of flaps
used for vulvar reconstruction in patients with advanced
and recurrent vulvar malignancies, focusing on the com-
plications related to the flaps and on the QoL and sur-
vival of patients.
Methods
From 1998 to 2013, patients with advanced and re-
current vulvar malignancies underwent vulvar recon-
struction using myocutaneous or skin flaps at the
Department of Obstetrics and Gynecology, Peking
Union Medical College Hospital. The patients’ out-
comes were evaluated. Clinical data were collected
and reviewed by searching the medical records, op-
erative notes, hospital discharge records and out-
patient clinic follow-up records. The histopathological
diagnosis was made and then reviewed by two experi-
enced pathologists. All 36 patients were re-staged ac-
cording to the revised International Federation of
Gynecology and Obstetrics (FIGO) stage 2009. Advanced
vulvar cancer was defined as a FIGO stage of ≥ III in this
study. The study was approved by the ethics committee at
Peking Union Medical College Hospital, Beijing, China.
Informed consent was obtained in written from the all the
participants in our study.
Surgical technique
The surgery plan was established by preoperative and
intraoperative consultation with plastic surgeons. Gyne-
cologic oncologists, urologists and colorectal surgeons
performed extirpative surgery before reconstruction. The
surgical margin was confirmed to be negative by frozen
section during the surgery before reconstruction. Once
the final defect was known, the plastic surgeon began to
evaluate the size and extent of the defect to design the
flaps for reconstruction. The laxity and quality of the
perineal skin were also evaluated. After careful evalu-
ation, different flap types were used for reconstruction.
An anterolateral thigh (ALT) flap was designed and har-
vested as previously described using a protocol sug-
gested by our team [4]. The other four flap types
including pudendal thigh flap (PTF), deep inferior epi-
gastric perforator (DIEP) flap, gracilis myocutaneous flap
and transverse rectus abdominis musculocutaneous
(TRAM) flap, were also harvested and used as previously
described [7–9]. The selection of different types of flaps
was based on the patients’ history, including prior irradi-
ation, history of vulvar surgery, history of cesarean
section, and nature of vulvar defects.
Post-operative care
All patients were required to undergo bed rest for 5 to
7 days after the operation and maintain hip-flexion and
the genuflecting position to relieve the pressure on the
flaps. The patients were then encouraged to participate
in bedside walking. The plastic surgeon carefully
checked the color and temperature of the flap every day
until flap survival was confirmed. The Foley catheter
remained in place for at least 7 days. Patients with close
surgical margins [10] , high-risk factors [10, 11] and
patients with negative surgical margins according to fro-
zen section during surgeries that turned into positive in
post-operative pathological examinations were given
post-operative adjuvant treatment.
Follow-up plan
After discharge, a gynecologic oncologist and plastic
surgeon followed up the patients at an outpatient clinic
1-month after surgery. The patients were then followed
at the gynecologic oncology clinic every 3 months for
the first 2 years and then every 6 months for 3–5 years.
The follow-up evaluation involved a complete history,
physical and gynecological examination, laboratory
examination, and pelvic and abdominal ultrasonography.
Biopsies were performed if recurrence was suspected.
Local recurrence was confirmed by pathological examin-
ation, and distant metastasis was diagnosed by positron
emission tomography-computed tomography (PET-CT)
and/or computed tomography (CT). Progression-free
survival (PFS) was defined as the time interval from the
date of vulva reconstruction to the date of disease pro-
gression or recurrence. Overall survival (OS) was defined
as the time interval from the date of the primary surgery
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to the date of death or last contact. The follow-up dead-
line was 30 June, 2014.
QoL and post-operative complications
The QoL assessment focused on disease-specific pain
and performance status. The degree of pain was eval-
uated with a four-category verbal rating scale (VRS-
4)( 0 = no pain, 1 = mild pain, 2 = moderate pain, and
3 = severe or intense pain) [12, 13]. The performance
status was determined using the Eastern Cooperative
Oncology Group/World Health Organization/Zubrod
(ZUBROD-ECOG-WHO) scale (0 = normal activity; 1 =
symptoms, but nearly ambulatory; 2 = some bed time, but
needs to be in bed for < 50 % of the normal daytime;
3 = needs to be in bed for > 50 % of the normal day-
time and 4 = unable to get out of bed) [14]. The
VRS-4 and performance status were evaluated before
surgery and 1 month after surgery.
Plastic surgeons evaluated flap-associated complica-
tions during the hospital stay and after discharge from
the hospital at the outpatient plastic surgery department.
Postoperative complications were defined as major or
minor according to a previous study [15]. Major compli-
cations included total or partial flap necrosis, major
wound of dehiscence more than one- third of the inci-
sion length,and persistent dead space. Persistent dead
space is defined as dead space requiring a supplementary
reconstructive procedure during the follow-up period.
Minor complications included minor dehiscence of less
than one-third of the incision length that healed after
debridement [15]. Hematoma, seroma, cellulitis and
abscess were also considered complications. In this
study, we considered complications requiring reopera-
tion as major complications and those requiring debride-
ment or dressing changes as minor complications.
Necrosis was defined as clinical evidence of dead tissue
due to circulatory ischemic factors [6]. Dehiscence was
defined as the separation of surgical margins [6].
Statistical analysis
The patient age, operation time, length of hospitalization,
flap sizes, time of follow-up, survival curve and 5-year sur-
vival were statistically analyzed by SPSS software version
13.0 (SPSS, Inc., Chicago, IL, USA). Kaplan–Meier sur-
vival plots and Student’s two-tailed t-test were used for
paired data; the independent samples t test was also used.
A P value of <0.05 was considered statistically significant.
Results
Patients’ characteristics
Forty flaps were performed in 36 patients. Basic demo-
graphic and clinical information are shown in Table 1,
including age, FIGO stage, histological type, time of
reconstruction, prior irradiation, and flap type. The
mean age of the patients was 49 years. The main histo-
logical tumor type was squamous cell carcinoma
(72.22 %). Seven patients underwent vulvar reconstruction
at the time of primary treatment for advanced vulvar ma-
lignancies. Twenty-nine patients underwent vulvar recon-
struction after surgery for tumor recurrence (Fig. 1).
Twenty of the 36 patients (55.56 %) received chemo-
irradiation or radiation before vulvar reconstruction.
Thirty-two patients had only one skin flap type and four
patients had two different types. Among patients with a
single skin flap type, the ALT flap was the most commonly
Table 1 Basic demographic and clinical information of the 36
patients
Characteristics Number (%)
Mean age(year) 49.7 ± 13 (23–74)
Mean BMI 24.17 ± 4.64 (18.66–36.13)
FIGO stage
I 7 (19.44 %)
II 5 (13.89 %)
ΙΙΙ 12 (33.33 %)
ΙV 2 (5.56 %)
Unstaged 10 (27.78 %)
Histology
Squamous cell carcinoma 26 (72.22 %)
Melanoma 3 (8.33 %)
Bartholin gland carcinoma 2 (5.56 %)
Sarcoma 2 (5.56 %)
Others 3 (8.33 %)
Time of reconstruction
Primary treatment 7 (19.44 %)
After recurrence 29 (80.56 %)
Previous radiation
Yes 20 (55.56 %)
No 16 (44.44 %)
Types of skin flap
Anterolateral thigh flap(ALT) 21 (58.33 %)
Pudendal thigh flap(PTF) 6 (16.67 %)a
Deep omferior epigastric perforator (DIEP) 4 (11.11 %)
Gracilis myocutaneous flap 1 (2.78 %)





Involving the vaginal canal 7
Involving the urethral canal 4
aSCC squamous cell carcinoma, PENT primitive neuroectodermal tumor, MEHE
malignant epithelioid hemangioendotheliom
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used flap (21/36 cases, 58.33 %). Four patients had two
flap types: an ALT flap combined with a DIEP flap, TRAM
flap or gracilis myocutaneous flap; and one had a DIEP
flap combined with a PTF.
The mean operation time among all 36 patients was
338 min (range, 120–660 min) with a mean estimated
blood loss of 342 ml (range, 50–2000 ml). The flap size,
operation time and blood loss associated with each
different flap are shown in Table 2. The median length
of hospitalization was 31 days (range, 13–145 days).
Improvement in QoL and post-operative complications
All 36 patients had one or more symptoms that signifi-
cantly influenced their QoL before reconstruction, in-
cluding 23 (63.90 %) with pain, 3 (8.00 %) with pruritus,
18 (50.00 %) with ulceration, 6 (16.67 %) with edema,
and 6 (16.67 %) with vulvar hemorrhage. Five patients
(13.89 %) could not sit, sleep or walk without analgesics,
and one patient was unable to get out of bed. The
tumor-related symptoms in the other 30 patients
(83.33 %) were completely removed. After surgery, no
patient felt pruritus, ulceration,edema or hemorrhage.
For 23 patients suffered pain before surgery, 17 patients
were completely relived and 6 patients (16.67 %) still felt
slight pain. The mean VRS-4 score among all 36 pa-
tients was 1.44 before reconstruction and decreased to
0.17 after surgery (P < 0.0001). The mean performance
status was 1.67 before surgery and improved to 0.31
after surgery (P < 0.0001) (Table 3).
None of the patients experienced complete flap loss.
Eleven patients (30.56 %) developed complications, includ-
ing 5 patients (13.89 %) with major complication and 6 pa-
tients (16.67 %) with minor complication. All patients who
developed partial necrosis (13.89 %) underwent reoperation.
More specifically, 5 patients (13.89 %) suffered partial ne-
crosis, 5 (13.89 %) with minimal wound dehiscence and 1
(2.78 %) with flap cellulitis. All patients who developed par-
tial necrosis (13.89 %) underwent reoperation. The most
Fig. 1 The patient underwent vulvar reconstruction for recurrent squamous cell carcinoma (SCC) after tumor resection. a Flap design, b Perforator
dissection (c) Detection of the perforators and flap design (D) Appearance of the vulvae after reconstruction
Table 2 Comparison of different flap parameters
Flap parameters ALT DIEP PTF Gracilis Flap
Flap size (cm2) 179.21 ± 108.73 151 ± 67.12 70 ± 24.72 84
Operation time (min) 371.25 ± 38.72 300 ± 129.6 280.2 ± 140.4 240
Blood loss (ml) 278.13 ± 317.79 575 ± 403.1 175 ± 781.9 100
ALT anterolateral thigh, PTF pudendal thigh flap, DIEP deep inferior epigastric perforator
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common symptoms of partial necrosis were a pale flap
color and low flap temperature of flap followed by cyan-
osis, blisters, or swelling. Most cases of minimal dehis-
cence were found after removing the sutures. Among the
patients with major complications, four had an ALT flap
and one had a PTF flap. Among the patients with minor
complications, three had an ALT flap and one each had a
TRAM flap, DIEP flap and PTF. All patients who devel-
oped partial necrosis underwent reoperation, and five pa-
tients with minimal wound dehiscence were treated with
dressing changes. The case of cellulitis resolved after de-
bridement and dressing changes. All wounds healed favor-
ably after appropriate treatment. Twenty-one patients
received adjuvant therapies, such as chemotherapy and
radiotherapy. Among patients who received chemother-
apy, the mean time interval between surgery and adjuvant
therapy was 16 days. Among patients who received radio-
therapy, the mean interval was 29 days. The reconstructed
vulvae were plump and elastic. The donor sites healed
without functional impairment, and no donor site morbid-
ity was reported. No late complications were recorded.
One patient with a PTF reported perineal strain upon
sitting.
Follow-up results
The median follow-up duration was 9 months (range, 1–
75 months) after vulvar reconstruction. Twenty-one
patients (58.33 %) were confirmed to have relapsed after
vulvar reconstruction. Sixteen patients had local recur-
rence, five developed distant metastasis to the bilateral
lungs or liver. The other 15 patients were living and
disease-free at a median follow-up of 14 months (range,
1–60 months). Of all 36 patients, 21 patients (58.33 %)
had died at the last time of contact; 20 of them died of
recurrence and 1 died of myocardial infarction. The
median overall follow-up time was 43 months (range, 7–
206 months). The median progression-free survival
(PFS) was 5 months, and the median overall survival was
62 months. The 5-year survival rate of the 36 patients
was 53.8 % (Fig. 2).
Discussion
Commonly used reconstructive options include skin
grafts, local skin flaps and myocutaneous flaps [16]. Each
of these has advantages and limitations in different re-
construction situations. For example, skin grafts are
most useful for superficial defects, but their use is lim-
ited in patients with major resections. Additionally, local
Fig. 2 Kaplan-Meier survival curve showing the survival of the 36 patients
Table 3 Mean VRS-4 and mean performance status before and
after surgery
Before surgery After surgery P value
Mean VRS-4 1.44 ± 0.88 0.17 ± 0.34 P < 0.0001
Mean Performance status 1.67 ± 0.89 0.31 ± 0.89 P < 0.0001
VRS-4 four-category verbal rating scale
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flaps and regional flaps have been described in many
vulvar reconstructions, including V-Y flaps [6], inferior
gluteal flaps [17], and lotus petal flap [18, 19]. Applica-
tion of these flaps in vulvar reconstruction has produced
good outcomes with short hospital stays and low com-
plication rates. However, most such flaps are relatively
small in size, and their use is influenced by the surgical
history of the donor site, especially in irradiated tissue
[20, 21]. Myocutaneous flaps include the TRAM flap
and gracilis myocutaneous flap. The DIEP flap [22] and
ALT flap are perforator skin flaps, while the PTF is a
fasciocutaneous flap. However, prior irradiation, a his-
tory of surgery, and certain situations may also limit or
preclude the use of these flaps. The ALT flap was first
described by Song et al. [23] in 1984. It is a large skin
flap based on the septocutaneous artery flap concept
that can safely be harvested and provide sufficient tissue
to fill large defects [4, 24, 25]. Because of its reliability
and versatility, it has been successfully used in many soft
tissue reconstructions, such as those in the head and
neck region [26, 27]; however, there are relatively few
descriptions of the use of ALT flaps for treatment of
gynecologic malignancies.
For advanced and locally recurrent vulvar malignan-
cies, surgical treatment, which provides acceptable
survival results, is still the most common treatment
[20–22]. Although radical surgery can completely re-
move the tumor, it is associated with complications
such as wound infection, delayed wound healing, and
an increased hospital stay. Successful wound healing
is critical to minimizing patient morbidity and ensur-
ing that adjuvant therapies can be performed without
delay. Additionally, vulvar surgery often introduces
problems with regard to QoL and body image.[23].
Therefore, oncological vulvar reconstruction is neces-
sary to improve surgical outcomes and QoL.
Many studies have focused on different methods of
vulvar reconstruction, such as those using skin grafts,
local skin flaps or regional skin flaps [6, 24, 25]. The
most commonly used flaps are V-Y flaps [6], lotus petal
flaps [18] and PTF. The choice of surgical approach and
flap type depend on many factors, such as the patients’
prior treatment and surgery, which need to be carefully
reviewed when formulating a reconstructive plan.
Patients who have received radiotherapy often exhibit
poor vascularization in the radiation field which limits
the use of local and regional flaps.
In this study, we evaluated a consecutive series of 36
patients treated with 5 types of flaps for oncological
vulvar reconstruction. The majority of patients had
recurrence or a history of radiotherapy. Because of their
treatment history and disease status, there was little use
of local flaps; all patients underwent repair with regional
skin flaps. Staiano et al. [25] published a series on vulvar
reconstruction; most of the patients in their study had
received radiotherapy. There were minor complications
in 40 % of patients, and a local flap was used in 10
patients [25]. By comparison, although most of the
patients in our study received radiotherapy, there were
minor complications in only 13.89 % of the patients.
This may be because all of the patients had a regional
flap that was less influenced by prior irradiation. Add-
itionally, no functional impairment occurred in our
study. Hence, for patients with a history of irradiation,
flap reconstruction is a safer option, especially that using
a distant pedicle flaps. This method may offer a better
chance of healing.
Patients with vulvar cancer are often in pain, which in-
fluences the patients’ QoL. In this study, all patients’
VRS-4 score and performance status were evaluated be-
fore and after surgery. The mean VRS-4 score was 1.44
before reconstruction and 0.17 after surgery (P < 0.0001).
The performance status was 1.67 before surgery and im-
proved to 0.31 after surgery (P < 0.0001). Most of the
tumor-related symptoms were gone after surgery. Our
results demonstrate that vulvar reconstruction signifi-
cantly improved the patients’ QoL, which is very import-
ant for patients with advanced and recurrent diseases.
In previous studies, the survival rates of patients with
vulvar carcinoma and positive inguinal lymph nodes
ranged from 21 to 53 % [26–28]. Although most patients
were in the late stage and had recurrent tumors, the 5-
year survival rate of our 36 patients reached 53.8 %. This
demonstrates that with good pre-operative evaluation
and post-operative management, patients with advanced
and local recurrence can benefit from radical excision
and vulvar reconstruction.
Our experience with the present a series of cases
allowed us to develop a reconstructive approach for dif-
ferent vulvar defects. The choice of surgical approach
and flap type depends on many factors. A careful review
of patients’ conditions and prior histories is needed. In
the present study, defects were defined as simple defect
(localized soft-tissue deficiencies) and complicated
defects (irradiated defects or extensive soft-tissue defi-
ciencies). Simple defects can be reconstructed with local
flaps or ALT flap. For bilateral vulvar defects, fenestrated
or split ALT flaps also work well. For complicated
defects, ALT flaps can be elevated with customized
dimensions and components tailored to each defect [4].
For mons pubis defects, the DIEP flap and groin flap are
better choices.
Our study has some limitations, such as the lack of
information about sexual function because most pa-
tients are unwilling to share this information. Sexual
function after vulvar reconstruction is a very import-
ant factor in assessing improvement in QoL and is
worthy of further investigation.
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Conclusion
The use of myocutaneous/skin flap for vulvar recon-
struction after removal of advanced or recurrent vul-
var malignances is associated with a low rate of
postoperative complications decreased pain and an
improved functional status. Although the recurrence
rate in this patient population is high, a reasonable
proportion of patients who undergo resection for
advanced/recurrent vulvar cancer and reconstructive
surgery appear to benefit.
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